Betta Pharmaceuticals Co., Ltd. Class A

Betta Pharmaceuticals Co., Ltd. Class A

SSZSE:300558
43.25
CNY
-1.66
(-3.70%)
0.59EPS
79.80P/E
21.37BMarket Cap
Apr 28Next Earn

Total Valuation

CNY

As of September 30, 2026, Betta Pharmaceuticals Co., Ltd. Class A carries a market capitalization of 21.37B, placing it among publicly traded companies globally. Its enterprise value stands at 23.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap21.37B
Enterprise Value23.08B

Important Dates

Betta Pharmaceuticals Co., Ltd. Class A's next confirmed earnings release is scheduled for April 28, 2027.

Earnings Date4/28/2027

Share Statistics

As of September 30, 2026, Betta Pharmaceuticals Co., Ltd. Class A has 423.33M shares outstanding.

Shares Outstanding423.33M

Valuation Ratios

As of September 30, 2026, Betta Pharmaceuticals Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 79.80. The price-to-sales ratio is 5.60, and the price-to-book ratio stands at 3.27.

PE Ratio79.80
PS Ratio5.60
PB Ratio3.27
P/TBV Ratio6.10

Enterprise Valuation

As of September 30, 2026, Betta Pharmaceuticals Co., Ltd. Class A trades at an EV/EBITDA multiple of 56.96 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.07 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 56.96 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 23.08B versus a market cap of 21.37B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales6.07
EV / EBITDA56.96
EV / EBIT56.96

Financial Position

As of September 30, 2026, Betta Pharmaceuticals Co., Ltd. Class A maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 36.81, indicating elevated leverage, while an interest coverage ratio of 5.57 demonstrates adequate ability to service its debt obligations.

Current Ratio1.00
Quick Ratio0.34
Debt / Equity36.81
Debt / EBITDA5.95
Interest Coverage5.57

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Betta Pharmaceuticals Co., Ltd. Class A posted a return on equity (ROE) of 4.40, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.94 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.74, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.86, useful for judging operating efficiency across full business cycles. The company generates approximately 2.13M in revenue per employee across its workforce of 1,785.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.54 indicates how many times Betta Pharmaceuticals Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)4.40
Return on Assets (ROA)2.74
Return on Invested Capital (ROIC)2.94
Return on Capital Employed (ROCE)3.86
Revenue Per Employee2.13M
Employee Count1,785.00
Inventory Turnover2.54

Taxes

CNY

Over the twelve months ended September 30, 2026, Betta Pharmaceuticals Co., Ltd. Class A recorded 151.13M in income tax expense. That works out to an effective tax rate of 37.60, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 401.90M, leaving 266.66M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax151.13M
Effective Tax Rate37.60

Stock Price Statistics

CNY

As of the close on November 17, 2026, Betta Pharmaceuticals Co., Ltd. Class A's stock has declined approximately 17.32% over the past 52 weeks. The 50-day moving average sits at 45.85, while the 200-day moving average is 50.33.

52-Week Price Change-17.32%
50-Day Moving Average45.85
200-Day Moving Average50.33

Income Statement

CNY

Over the twelve months ended September 30, 2026, Betta Pharmaceuticals Co., Ltd. Class A generated 3.80B in revenue and converted that into 266.66M in net income, yielding earnings per share of 0.59. EBITDA reached 405.25M, while operating income came in at 638.90M.

Revenue3.80B
Gross Profit2.88B
Operating Income638.90M
Pretax Income401.90M
Net Income266.66M
EBITDA405.25M
EBIT405.25M
Earnings Per Share (EPS)0.59

Balance Sheet

CNY

As of September 30, 2026, Betta Pharmaceuticals Co., Ltd. Class A holds 706.36M in cash and equivalents against 2.41B in total debt, resulting in a net debt position of 508.84M. Total book value stands at 6.54B, with working capital of -8.56M providing operational flexibility.

Cash & Cash Equivalents706.36M
Total Debt2.41B
Net Debt508.84M
Equity (Book Value)6.54B
Book Value Per Share15.44
Working Capital-8.56M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-550.00M

Margins

Over the twelve months ended September 30, 2026, Betta Pharmaceuticals Co., Ltd. Class A posted a gross margin of 75.63, reflecting its pricing power and cost economics. The operating margin of 16.80 and net profit margin of 7.01 provide insight into operational efficiency.

Gross Margin75.63
Operating Margin16.80
Pretax Margin10.57
Profit Margin7.01
EBITDA Margin10.66

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Betta Pharmaceuticals Co., Ltd. Class A paid dividends of 0.30 per share. The dividend payout ratio of 54.13 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.36, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Betta Pharmaceuticals Co., Ltd. Class A shareholders.

Dividend Per Share0.30
Payout Ratio54.13
Shareholder Yield0.36

Scores

As of September 30, 2026, Betta Pharmaceuticals Co., Ltd. Class A has an Altman Z-Score of 4.87, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.87